A Phase 3, Double-Blind, Placebo-Controlled, Randomized Study to Assess the Safety of Epicutaneous Immunotherapy with DBV712 250 µg in 1-through 3-year-old Children with Peanut Allergy (COMFORT Toddlers)

Authors
Category Primary study
Registry of TrialsClinical Trials Information System
Year 2026
This article has no abstract
Epistemonikos ID: 9dc447ebd1bc4696762018361706acdcda74d4a2
First added on: Jan 17, 2026